In a groundbreaking development, researchers in the UK have reported the first-ever successful treatment for Huntington’s disease, a hereditary neurodegenerative disorder previously deemed incurable. The experimental gene therapy, known as AMT-130, slowed disease progression by 75% over three years, offering renewed hope to patients and families affected by the condition.
What Is Huntington’s Disease?
Huntington’s disease is a progressive neurological disorder caused by a mutation in the HTT gene, leading to the production of a toxic protein that damages brain cells. Symptoms typically manifest in mid-adulthood and include motor dysfunction, cognitive decline, and psychiatric disturbances. The disease is fatal, with patients often succumbing within 15–20 years of symptom onset.
The Breakthrough Treatment
Led by Professor Sarah Tabrizi at University College London (UCL), the pioneering clinical trial utilised an innovative gene therapy approach. The treatment involves a one-time surgical procedure lasting up to 20 hours, during which a specially engineered, harmless virus is infused directly into the brain. This virus carries a DNA strand designed to deactivate the mutant huntingtin protein responsible for the disease.
The results have been nothing short of remarkable. According to a press release from UCL, patients who underwent the treatment experienced a 75% reduction in the expected progression of the disease over a three-year period. Instead of the expected rapid decline, these patients maintained neurological function, effectively gaining years of quality life.
Expert Insights
Professor Tabrizi expressed her astonishment at the results, stating, ‘We never in our wildest dreams would have expected a 75% slowing of clinical progression.’ She emphasised that this breakthrough could pave the way for earlier interventions, potentially preventing the onset of symptoms altogether.
Where to Access Huntington’s Disease Treatment in the UK
For individuals seeking treatment or support for Huntington’s disease, the UK offers several renowned centres specialising in diagnosis, care, and research:
University College London (UCL) Institute of Neurology: A leading research and clinical centre focusing on Huntington’s disease, offering multidisciplinary care and conducting pioneering clinical trials.
Cardiff University Huntington’s Disease Centre: A prominent centre dedicated to research and coordination of Huntington’s disease studies across South Wales.
Royal Hospital for Neuro-disability: Specialises in providing care and support for patients with complex needs due to Huntington’s disease.
Guy’s and St Thomas’ NHS Foundation Trust: Offers follow-up services for individuals diagnosed with Huntington’s disease, including participation in clinical trials.
These institutions are at the forefront of Huntington’s disease care and research, providing essential services to patients and families affected by the condition.
Global Implications
Approximately 6,000 to 10,000 individuals in the UK are affected by Huntington’s disease, with many more at risk due to family history. The success of this gene therapy trial has the potential to revolutionise treatment approaches globally.
Biotechnology company UniQure plans to seek approval for the therapy in the United States, signalling a new era in the fight against this devastating disorder.
Looking Ahead
While gene therapy presents a promising avenue for treatment, the procedure remains complex and expensive. As the medical community continues to assess its long-term efficacy and accessibility, this breakthrough stands as a powerful testament to scientific innovation and its potential to transform lives.
Originally published on IBTimes UK
